Anas Younes

Intercept Pharmaceuticals (United States)

Also affiliated with New York Chiropractic College

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 18 papers. Top paper: “Positron-emission tomography–based staging reduces the prognostic impact of early disease progression in patients with follicular lymphoma”.

Positron-emission tomography–based staging reduces the prognostic impact of early disease progression in patients with follicular lymphoma

European Journal of Cancer(2020)10.1016/j.ejca.2019.12.006

N/A

1.3DataRank · unranked

29 citations

Fushen Sha, Anna Alperovich, Ai Ni, Katy Smith, Zhitao Ying +20 more

Phase I/Ib Study of the Efficacy and Safety of Buparlisib and Ibrutinib Therapy in MCL, FL, and DLBCL with Serial Cell-Free DNA Monitoring

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-21-2183

N/A

0.850DataRank · unranked

22 citations

Laure Michaud, Karissa Whiting, Reiko Nakajima, Chelsea Nichols, Stephanie De Frank +19 more

TP53 mutations and RNA-binding protein MUSASHI-2 drive resistance to PRMT5-targeted therapy in B-cell lymphoma

Nature Communications(2022)10.1038/s41467-022-33137-8

N/A

0.510DataRank · unranked

29 citations

Chiara M. Evans, Daniel Zakheim, Eren L. Chu, Alice Yunsi Refermat, Zahra Asgari +18 more

Clinical outcomes with use of radiation therapy and risk of transformation in early-stage follicular lymphoma

Blood Cancer Journal(2022)10.1038/s41408-022-00620-w

N/A

0.291DataRank · unranked

5 citations

Michelle Okwali, Anna Alperovich, Philip Caron, Lorenzo Falchi, Audrey Hamilton +22 more

ASN007 is a selective ERK1/2 inhibitor with preferential activity against RAS-and RAF-mutant tumors

Cell Reports Medicine(2021)10.1016/j.xcrm.2021.100350

N/A

0DataRank · unranked

24 citations

Scott K. Thompson, Roger A. Smith, Mariana Da Silva Ferreira, Zahra Asgari, Andrea Knežević +7 more

A phase 1 trial of copanlisib plus ibrutinib in relapsed/refractory mantle cell lymphoma

Blood Advances(2022)10.1182/bloodadvances.2021006555

N/A

0DataRank · unranked

6 citations

Hiu Ying Lam, Karissa Whiting, Anita Kumar, Matthew J. Matasar, Colette Owens +10 more

Enhanced clinical assessment of hematologic malignancies through routine paired tumor:normal sequencing

medRxiv(2022)10.1101/2022.10.03.22280675

N/A

0DataRank · unranked

1 citations

Mark D. Ewalt, Gowtham Jayakumaran, Iwona Kiecka, Anita S. Bowman, JinJuan Yao +50 more

Enhanced clinical assessment of hematologic malignancies through routine paired tumor:normal sequencing

Research Square(2022)10.21203/rs.3.rs-2094202/v1

N/A

0DataRank · unranked

0 citations

Mark D. Ewalt, Gowtham Jayakumaran, Iwona Kiecka, Anita S. Bowman, JinJuan Yao +50 more

Potentiating antibody-dependent killing of cancers with CAR T cells secreting CD47-SIRPα checkpoint blocker

Blood(2023)10.1182/blood.2022016101

N/A

0DataRank · unranked

47 citations

Keifer G. Kurtz, Patrick Wallisch, Stephanie Pierre, Shireen Khayat, Christopher M. Bourne +6 more

Enhanced clinical assessment of hematologic malignancies through routine paired tumor and normal sequencing

Nature Communications(2023)10.1038/s41467-023-42585-9

N/A

0DataRank · unranked

29 citations

Mark D. Ewalt, Gowtham Jayakumaran, Iwona Kiecka, Anita S. Bowman, JinJuan Yao +50 more

Synthetic lethality of drug-induced polyploidy and BCL-2 inhibition in lymphoma

Nature Communications(2023)10.1038/s41467-023-37216-2

N/A

0DataRank · unranked

14 citations

Mariana Da Silva Ferreira, Tatiana Erazo, Man Jiang, Zahra Asgari, Elisa de Stanchina +3 more

Molecularly targeted epigenetic therapy with mocetinostat in relapsed and refractory non-Hodgkin lymphoma with CREBBP or EP300 mutations: an open label phase II study

Leukemia & lymphoma/Leukemia and lymphoma(2023)10.1080/10428194.2022.2164194

N/A

0DataRank · unranked

9 citations

Ariela Noy, David J. Straus, Matthew J. Matasar, Craig H. Moskowitz, Venkatraman Seshan +6 more

Data from Phase I/Ib Study of the Efficacy and Safety of Buparlisib and Ibrutinib Therapy in MCL, FL, and DLBCL with Serial Cell-Free DNA Monitoring

(2023)10.1158/1078-0432.c.6530889.v1

N/A

0DataRank · unranked

0 citations

Laure Michaud, Karissa Whiting, Reiko Nakajima, Chelsea Nichols, Stephanie De Frank +19 more

Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups

Blood Cancer Journal(2020)10.1038/s41408-020-00340-z

N/A

0DataRank · unranked

203 citations

Fushen Sha, Anna Alperovich, Ai Ni, Katy Smith, Zhitao Ying +20 more

SETD1B mutations confer apoptosis resistance and BCL2 independence in B cell lymphoma

The Journal of Experimental Medicine(2024)10.1084/jem.20231143

N/A

0DataRank · unranked

11 citations

Shenqiu Wang, Sara Parsa, Man Jiang, Alexander N. Gorelick, Sagarajit Mohanty +14 more

Selective Inhibition of HDAC3 Targets Synthetic Vulnerabilities and Activates Immune Surveillance in Lymphoma

Cancer Discovery(2020)10.1158/2159-8290.cd-19-0116

N/A

0DataRank · unranked

159 citations

Saber Tadros, Matt Teater, Lorena Fontán, Aaron Y. Chang, Neeraj Jain +24 more

Tumor-targeted nanoparticles improve the therapeutic index of BCL2 and MCL1 dual inhibition

Blood(2020)10.1182/blood.2020008017

N/A

0DataRank · unranked

36 citations

Mandana T. Manzari, Laurie Herviou, Mariana Da Silva Ferreira, Connor J. Hagen, Hiroto Kiguchi +6 more

A phase I and randomized phase II etctn study of KW-0761 (Mogamulizumab) and MK-3475 (Pembrolizumab) in relapsed and refractory diffuse large B-cell lymphoma.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.tps8072

N/A

0DataRank · unranked

5 citations

Santosha A. Vardhana, Anita Kumar, Mehrdad Abedi, Rasmus T. Hoeg, Elad Sharon +2 more